CA3247035A1 - COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS - Google Patents

COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS

Info

Publication number
CA3247035A1
CA3247035A1 CA3247035A CA3247035A CA3247035A1 CA 3247035 A1 CA3247035 A1 CA 3247035A1 CA 3247035 A CA3247035 A CA 3247035A CA 3247035 A CA3247035 A CA 3247035A CA 3247035 A1 CA3247035 A1 CA 3247035A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
methyl
indol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247035A
Other languages
English (en)
French (fr)
Inventor
Michael Palfreyman
Alex Nivorozhkin
Brett J. GREENE
Robert Mino
Amy Claire Reichelt
Geoffrey B. Varty
Original Assignee
Cybin IRL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin IRL Ltd filed Critical Cybin IRL Ltd
Publication of CA3247035A1 publication Critical patent/CA3247035A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3247035A 2022-03-31 2023-03-29 COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS Pending CA3247035A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362258P 2022-03-31 2022-03-31
US63/362,258 2022-03-31
PCT/EP2023/058107 WO2023186963A1 (en) 2022-03-31 2023-03-29 Combination of nitrous oxide and 5-ht2a receptor agonists

Publications (1)

Publication Number Publication Date
CA3247035A1 true CA3247035A1 (en) 2023-10-05

Family

ID=86007250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247035A Pending CA3247035A1 (en) 2022-03-31 2023-03-29 COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS

Country Status (5)

Country Link
EP (1) EP4499087A1 (https=)
JP (1) JP2025510942A (https=)
AU (1) AU2023242469A1 (https=)
CA (1) CA3247035A1 (https=)
WO (1) WO2023186963A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
EP4704806A1 (en) * 2023-05-05 2026-03-11 Cybin IRL Limited Injectable pharmaceutical formulations
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
DE4023108C1 (https=) 1990-07-20 1992-02-13 Ems Gmbh, 8520 Moehrendorf, De
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
WO2003026559A2 (en) 2001-09-28 2003-04-03 Kurve Technology, Inc Nasal nebulizer
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
US8826905B2 (en) 2007-06-01 2014-09-09 Ramses Nashed Respiratory face mask and breathing circuit assembly
US20100192947A1 (en) 2009-02-04 2010-08-05 Jeff Mandel Anesthetic delivery system and methods of use
CA2763021C (en) 2010-02-22 2013-03-05 Class 1 Inc. Apparatus, systems and methods for collecting and reclaiming anaesthetic agents and for removing nitrous oxide from exhaust gases
EP2589403B1 (en) 2011-05-31 2016-02-03 Ishikita, Naoyuki Anesthetic inhalation-assisting device
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний

Also Published As

Publication number Publication date
EP4499087A1 (en) 2025-02-05
AU2023242469A1 (en) 2024-09-05
WO2023186963A1 (en) 2023-10-05
JP2025510942A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
AU2022342266B2 (en) Combination drug therapies
US20250213527A1 (en) Formulations of psilocybin analogs and methods of use
CA3247035A1 (en) COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS
EP4479372A1 (en) Phenethylamine derivatives, compositions, and methods of use
US20250236589A1 (en) Therapeutic phenethylamine compositions and methods of use
AU2023207801B2 (en) Tryptamine compositions and methods
AU2023366306A1 (en) Phenethylamine compounds, compositions, and methods of use
WO2024046837A1 (en) Tryptamine compounds, compositions, and methods of use
EP4499071A1 (en) Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
JP2026513655A (ja) フェネチルアミン化合物、組成物、及び使用方法
CN118632835A (zh) 色胺组合物和方法

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240927

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241015

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241015

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241015

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305